SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: ajcmr who wrote (69)2/2/1997 2:21:00 AM
From: Joe Stephenson   of 1321
 
The stock has been moving up gradually over the past few weeks. There are approvals pending in a couple of European markets (Italy and Germany) for Photofrin that are expected in the 1st half of '97. Also, and perhaps more importantly, there may be an ODAC (subcommittee of the FDA)hearing by the end of 2Q on the use of Photofrin for Lung Cancer in the U.S. This would be a significant market approval.
The UBS report that came out in Sept. '96 gives a lot of detail on the status of the company.
Further down the road (late '98) will be results from the current Phase 3 trials of their 2nd generation drug BPD and it's use in treating AMD.

Cheers...Joe
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News